High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase as a Target for Intracellular Antimycobacterial Inhibitors by Christophe, Thierry et al.
High Content Screening Identifies Decaprenyl-
Phosphoribose 29 Epimerase as a Target for Intracellular
Antimycobacterial Inhibitors
Thierry Christophe
1, Mary Jackson
2, Hee Kyoung Jeon
1, Denis Fenistein
3, Monica Contreras-
Dominguez
4, Jaeseung Kim
5, Auguste Genovesio
3, Jean-Philippe Carralot
4, Fanny Ewann
4, Eun Hye
Kim
4, Sae Yeon Lee
5, Sunhee Kang
5, Min Jung Seo
5, Eun Jung Park
5, Henrieta S ˇkovierova ´
2, Ha Pham
2,
Giovanna Riccardi
6, Ji Youn Nam
1, Laurent Marsollier
7, Marie Kempf
7, Marie-Laure Joly-Guillou
7,
Taegwon Oh
8, Won Kyung Shin
8, Zaesung No
5, Ulf Nehrbass
1, Roland Brosch
9, Stewart T. Cole
10,
Priscille Brodin
4,9*
1Screening Technologies and Pharmacology, Institut Pasteur Korea, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, 2Mycobacteria Research Laboratories, Department
of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, United States of America, 3Image Mining, Institut Pasteur Korea, Bundang-
gu, Seongnam-si, Gyeonggi-do, Korea, 4Biology of Intracellular Pathogens Inserm Avenir Group, Institut Pasteur Korea, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea,
5Medicinal Chemistry, Institut Pasteur Korea, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, 6Dipartimento di Genetica e Microbiologia, Universita ` degli Studi di Pavia,
Pavia, Italy, 7Groupe d’Etude des Interactions Ho ˆte Pathoge `ne, Universite ´ d’Angers, Angers, France, 8International Tuberculosis Research Center, Masan, Korea, 9Institut
Pasteur, Integrated Mycobacterial Pathogenomics, Paris, France, 10Global Health Institute, Ecole Polytechnique Fe ´de ´rale de Lausanne, Lausanne, Switzerland
Abstract
A critical feature of Mycobacterium tuberculosis, the causative agent of human tuberculosis (TB), is its ability to survive and
multiply within macrophages, making these host cells an ideal niche for persisting microbes. Killing the intracellular tubercle
bacilli is a key requirement for efficient tuberculosis treatment, yet identifying potent inhibitors has been hampered by
labor-intensive techniques and lack of validated targets. Here, we present the development of a phenotypic cell-based assay
that uses automated confocal fluorescence microscopy for high throughput screening of chemicals that interfere with the
replication of M. tuberculosis within macrophages. Screening a library of 57,000 small molecules led to the identification of
135 active compounds with potent intracellular anti-mycobacterial efficacy and no host cell toxicity. Among these, the
dinitrobenzamide derivatives (DNB) showed high activity against M. tuberculosis, including extensively drug resistant (XDR)
strains. More importantly, we demonstrate that incubation of M. tuberculosis with DNB inhibited the formation of both
lipoarabinomannan and arabinogalactan, attributable to the inhibition of decaprenyl-phospho-arabinose synthesis
catalyzed by the decaprenyl-phosphoribose 29 epimerase DprE1/DprE2. Inhibition of this new target will likely contribute
to new therapeutic solutions against emerging XDR-TB. Beyond validating the high throughput/content screening
approach, our results open new avenues for finding the next generation of antimicrobials.
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Introduction
About one third of the world’s population is estimated to be
infected with Mycobacterium tuberculosis. In nine out of ten cases, M.
tuberculosis persists in a latent state throughout an individual’s
lifetime [1]. The bacillus is found in a variety of host cells such as
alveolar macrophages, dendritic cells and type II alveolar
pneumocytes in infected lungs [2,3,4], as well as in adipocytes
[5]. Whereas dendritic cells and adipocytes are not permissive for
in vitro growth, M. tuberculosis replicates actively in macrophages
and type II alveolar pneumocytes [2,3,5,6]. The ability of M.
tuberculosis to survive and multiply within host cells certainly
contributes to the pathogenesis of tuberculosis (TB).
Though the exact means of ensuring intracellular survival is still a
matter of debate [7,8,9], it is clear that potential new anti-
tuberculosis drugs have to be active against M. tuberculosis inside host
cells [10]. As this feature is not normally taken into account in
traditional drug-screening procedures at an early stage, we
developed a target-free cell-based assay suitable for high throughput
screening that enables an unbiased search for compounds that kill
intracellular M. tuberculosis without affecting the viability of the host
macrophage. Such molecules would then serve as tools to identify
novel druggable mycobacterial targets.
Target-based screens for antimicrobial agents have been
disappointing to date [11,12] whereas whole cell-based approaches
with M. tuberculosis are fraught with logistic difficulties and
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a rapid phenotypic assay based on the use of automated confocal
fluorescent microscopy to monitor intracellular growth of GFP-
expressing M. tuberculosis H37Rv in Raw264.7 macrophages. The
assay was set-up for the high throughput screening (HTS) of large
chemical libraries in 384-well format and its robustness was
validated with known antibiotics. By screening several thousand
small molecules, new series of compounds were identified as well
as some sharing structural similarities with known TB drugs.
Among these, the benzamide series was then used as a bait to
identify a new putative target. Using a combination of biochemical
assays and genetic approaches, we showed that nitrobenzamide
derivatives inhibited arabinan synthesis, which has not been
observed for any of TB drugs so far. Altogether, these results
demonstrate the feasibility of large scale screen for intracellular M.
tuberculosis growth and open new avenues for enriching the TB
drug pipeline as well as for finding new druggable targets.
Results
High Content Assay (HCA) Set-up based on the
Monitoring of M. tuberculosis Infection in Macrophages
To set up the optimal conditions of M. tuberculosis infec-
tion, Raw264.7 macrophages were first infected with mycobac-
teria that constitutively express green fluorescent protein (GFP)
using different multiplicities of infection followed by kinetic
analysis of intracellular bacterial growth. Confocal images of live
samples were acquired using an automated confocal microscope
(Opera
TM) over 7 days (Figure 1A). During the first twenty-four
hours, a few discrete weakly fluorescent bacteria localized within
the cells. At day 2, the average number of cells had increased and
mycobacteria had started to spread into neighboring cells leading
to zones of strongly fluorescent bacteria. At day 3, the number of
cells had significantly diminished and the bacteria formed large,
highly fluorescent aggregates, which covered almost the entire
image from day 5 onwards. As a control, non-infected cells grew
to confluence at day 2 and remained alive until day 5.
Customized image analysis was developed to automatically
quantify several different parameters such as the number of host
macrophages, the percentage of infected cells and the average
surface area of bacterial aggregates [13,14]. Representative
results of the cell segmentation method are displayed on
Figure 1B. After two hours of infection, between 2 and 10%
of Raw264.7 cells were found to harbor intracellular bacilli
(Figure S1A). The percentage of infected cells steadily increased
reaching 50% by day five with a MOI of 1. This augmentation
correlated with substantial macrophage mortality due to the
known cytopathogenic effects of M. tuberculosis [2] (Figure S1B).
From day 5 to day 7, the percentage of infected cells continued to
increase slowly up to 70%; however, the cell number dramatically
decreased. Therefore to ensure that a sufficient number of cells
was recorded in each field were recorded, the incubation time
with M. tuberculosis was set at 5 days for the next series of
experiments.
Pharmacological Validation with Known Antitubercular
Drugs
To validate the system, we first tested the effect of the standard
anti-tuberculosis drugs such as isoniazid (INH) and rifampin
(RIF) in our model (Figure 1C). As expected, these drugs
demonstrated a dose-dependent decrease in both bacterial load
and percentage of infected macrophages. Interestingly, an
increase in host cell number was seen at effective concentrations,
clearly demonstrating the ability of these drugs to prevent M.
tuberculosis induced cytopathogenicity (Figure 1D,E). Taking
into account both the amount of green fluorescent bacteria and
the host cell number, this assay enables a dual and independent
determination of intracellular anti-mycobacterial drug efficacy.
In addition, the reference drugs were also applied against M.
tuberculosis H37Rv-GFP grown in liquid broth without host cells.
No major differences in minimal inhibitory concentrations (MIC)
between the two assays were noticed for INH (Figure 1F),
ethambutol, ethionamide and PA-824 [15] (Table 1), whereas
RIF was 100-fold less efficient in the cell-based assay
(Figure 1G), confirming the previously reported reduced
activity of RIF against intracellular bacteria [16]. This finding
clearly demonstrates that our dual read-out, cell-based drug
screening system indeed measured the intracellular antibacterial
activity of drugs, which allowed us to further adapt the system
for High Throughput/Content Screening.
High Throughput/Content Screening (HT/CS)
A diverse library of 56,984 synthetic compounds was first
screened at a single concentration. A normal distribution of the
compounds was obtained using PCA-1x analysis (Figure 1H). 486
fully active hits were then confirmed by means of serial dilution
experiments. The MIC of each hit was then determined using both
the percentage of infected cells and the total cell number by taking
advantage of the dual visual effect described above as an
independent confirmation of compound activity. More than one-
quarter of the hits (135 hits) had an MIC less than 5 mM, and 8%
had a MIC below 1 mM, which is equivalent to that of INH
(Figure 1I). A few compounds, such as compound CPD1, showed
cytotoxicity at high concentrations as seen by a significant decrease
in the cell number above 5 mM( Figure S2C).
Chemo-informatic cluster analysis of the 135 hits was performed
and hits fell into 9 clusters plus 13 singletons (Table S1). The
largest cluster had 69 members with an isonicotinohydrazide
moiety similar to that of INH, used as a positive reference in our
assay, which validated our approach. The second largest cluster of
24 derivatives shares a common benzamide scaffold. As no
antimycobacterial effect had been previously reported for this
Author Summary
Tuberculosis is still a major threat to global health. The
disease in humans is caused by a bacterium, Mycobacte-
rium tuberculosis, and treatment of an infected individual
requires more than six months of chemotherapy. Because
such a long course of treatment is required, compliance is
low, which can result in the development of multidrug
resistant strains (MDR-TB) and even extremely resistant
strains (XDR-TB). Identifying new drug targets and
potential lead therapeutic compounds are needed to
combat MDR-XDR-TB. We developed a new type of assay
based on the visualization of mycobacterium replication
within host cells and applied it for the search of
compounds that are able to chase the pathogen from its
hideout. As a result, we found 20 new series of drug
candidates that are effective against the bacilli in its hiding
place, potentially addressing a crucial aspect in the
resilience of the disease. We also showed that one series
of compounds acts by inhibiting a key enzyme required for
the synthesis of an essential component from the
mycobacterial cell wall that is not targeted by any of the
commercially available antituberculosis drugs. Altogether,
our results pave the way for development of the next
generation of antibacterial agents.
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PLoS Pathogens | www.plospathogens.org 2 October 2009 | Volume 5 | Issue 10 | e1000645Figure 1. Monitoring of intracellular growth of tubercle bacilli inside macrophages by automated confocal microscopy and HT/CS
screening results and hit profile. (A) Pictures of Raw264.7 cells infected with M. tuberculosis H37Rv-GFP at different time points after infection. NI:
Non infected. Scale bar: 50 mm. (B) Infected Cell segmentation: 1: 2-color image; 2: cell mask detection, 3: purple cells correspond to infected cells. (C)
Pictures of M. tuberculosis H37Rv-GFP infected Raw264.7 cells at day 5 in presence of INH, RIF at 1 mg/mL or DMSO control (D–G) INH and RIF
pharmacology in intracellular (D, E) and in vitro (F ,G) assays. Bacterial load (arbitrary units, black circles), host cell number (gray circles) and
percentage of infected cells (black squares) represent main parameters determined by our customized image analysis for the intracellular assay. In
vitro M. tuberculosis growth is given in Relative Fluorescent Units (gray triangles). Results are representative of three independent experiments with
standard deviation (SD) and have been reproduced more than 50 times during the screening. (H) Distribution of primary screening results after PCA-
1x analysis. Yellow: INH 7 mM; Green: RIF 1.2 mM, blue: DMSO, red: screened compounds. (I) MIC range of the 486 confirmed hits.
doi:10.1371/journal.ppat.1000645.g001
Table 1. Comparison of MICs of known TB drugs in broth and in intracellular growth conditions.
Compound Name Mode of action/Target MW In vitro broth growth Intracellular macrophage growth
MIC (mg/mL) MIC (mM) MIC (mg/mL) MIC (mM) Cell toxicity (mM)
Isoniazid InhA, cell wall synthesis 137.1 0.16 1.2 0.16 1.2 .150
Ethionamide Cell wall synthesis 166.2 1 6.0 1 6.0 120
Rifampin RpoB, RNA polymerase 822.9 0.01 0.01 2.4 2.9 24
Rifabutin RpoB, RNA polymerase 877.0 0.01 0.01 0.1 0.11 .20
Ethambutol Cell wall synthesis 204.3 1 4.9 1 4.9 .20
PA-824 Hypoxia 359.3 0.08 0.22 0.08 0.22 .20
Pyrazinamide cell wall synthesis 123.1 .20 .150 .20 .150 .150
Streptomycin Protein synthesis 581.6 0.9 1.5 .20 .35 .35
Fusidic Acid Protein synthesis 515.7 0.5 1 10 20 .20
Amikacin Protein synthesis 585.6 0.04 0.07 .20 .150 .150
Levofloxacin DNA gyrase 361.4 0.9 2.5 .10 .20 .20
AX20017 pknG 264.3 .5 .20 .5 .20 .20
doi:10.1371/journal.ppat.1000645.t001
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synthesized for further studies.
Structure Activity Relationship (SAR) of Benzamides
Derivatives
To identify the chemical substituents necessary for benzamide
antibacterial activity, over 155 additional derivatives were
synthesized and their structure-activity relationship was analyzed
using both our intracellular assay and the in vitro growth assay. The
most potent compounds exhibited substitutions of the benzene
moiety with a nitro group at positions 3 and 5 (Figure 2 and
Figure S3). The reduction of one nitro- to hydroxylamine and
amino groups led to totally inactive compounds. In contrast,
derivatives with an N-substitution by benzyloxy-ethyl or by
phenoxy-ethyl showed enhanced activity with an MIC below
0.2 mM. More importantly, cyclic-benzamides had an MIC below
80 nM in the in vitro assay. However, these compounds turned out
to be much less potent in the intracellular assay. Furthermore,
substitution of the benzyloxy moiety by a chlorine- or fluorine
atoms at position 3 led to increased potency in both assays in
contrast to carboxyl substitutions. In parallel, we selected two
compounds, N-(2-(4-methoxyphenoxy) ethyl)-3,5-dinitrobenza-
mide (DNB1) and N-(2-(benzyloxy) ethyl)-3,5-dinitrobenzamide
(DNB2), for further mechanistic studies and target identification
(Figure 2).
Dinitrobenzamides (DNB) Activity on Intracellular Growth
of M. tuberculosis within Primary Macrophages and
Cytotoxicity
DNB1 and DNB2 were pursued further since their activities on
intra-cellular and extra-cellular M. tuberculosis were particularly
favorable (Figure 3A–C and Figure S3). Their effects on
primary macrophages were further determined. Host cells that had
been pre-incubated with DNB1 harbored fewer bacteria com-
pared to the DMSO control, and were more abundant at day 7 of
infection as shown in Figure 3D. Conventional CFU determi-
nation was then performed after seven days of infection to quantify
the remaining bacterial load. More than a ten-fold decrease in the
number of CFUs was observed with both human and mouse
primary cells at a DNB1 concentration above 5 mM( Figure 3E).
Similar data were obtained for DNB2 (data not shown). This
confirms the potency of this series of compounds. In parallel, no
cell toxicity was noted for these compounds using conventional
cytotoxicity assays of uninfected cells, indicating that our high
content assay can reliably predict cytotoxicity (Table S2).
Antimicrobial Effects of Dinitrobenzamides
Analysis of the broad antimicrobial spectrum was undertaken
and revealed that the effect of these dinitrobenzamide derivatives
was mainly restricted to actinomycetes with the most potent
activity observed against Mycobacterium with an MIC of 75 ng/mL
(0.2 mM) (Table S2). Of particular importance, DNB1 and DNB2
were also highly active against multidrug-resistant (MDR) and
extensively drug-resistant (XDR) clinical isolates. Moreover, these
two compounds were also associated with low levels of
spontaneous resistance. Resistant mutants arose at frequencies
between 1.2610
26 and 1610
28 on agar containing 2–166 the
MICs of DNB1 or DNB2, a frequency similar to that with INH
(Table S3). The potential for the development of resistance to
dinitrobenzamides, in vitro, is therefore analogous to major anti-TB
drugs.
Interestingly, the bactericidal effect on M. tuberculosis of DNB1
and DNB2 was found to be time-dependent (Figure S4A) and to
require several days to reach bacterial clearance, implying that
they could interfere with de novo mycobacterial component
biosynthesis. This is further corroborated by the fact that the
DNB compounds lost their activity in a non-replicating M.
tuberculosis system [17]. Altogether these results suggested that the
DNB compounds might act on different targets than current
antituberculosis compounds.
Effect of Dinitrobenzamides on Cell Wall Biosynthesis
To gain insight into the possible targets of dinitrobenzamides,
we investigated the effect of DNB1 and DNB2 on the lipid
composition of the cell envelope of M. tuberculosis; no effects on the
biosynthesis of fatty acids, mycolic acids and/or other lipids were
noted (data not shown). By contrast, DNB1 and DNB2 showed a
clear-cut effect on the synthesis of the arabinan domains of
arabinogalactan (AG) and lipoarabinomannan (LAM) (Figure
S4B,C). Decaprenyl-phospho-arabinose (DPA) is the only known
arabinofuranose (Araf) donor in the biogenesis of AG and LAM in
mycobacteria and is thus an essential precursor [18,19]. To
determine whether the effects of DNB were attributable to the
inhibition of the synthesis of DPA or to that of DPA-dependent
arabinosyltransferases involved in the elongation of both hetero-
polysaccharides, we set out to monitored DPA formation in
treated and untreated extracts of M. smegmatis mc
2155. Analyses
revealed complete inhibition of DPA formation in the DNB-
treated extracts concurrent with the accumulation of decaprenyl-
phospho-ribose (DPR) (Figure 3F), indicating that the target of
both DNB inhibitors is probably the heteromeric decaprenyl-
phospho-ribose 29 epimerase encoded by the rv3790c (dprE1)/
rv3791c (dprE2) genes in M. tuberculosis H37Rv [20]. DprE1 has
been recently described as the target of benzothiazinones (BTZ), a
new class of antitubercular unrelated nitro-compounds [21]. BTZ-
resistant mutants of M. smegmatis and M. bovis BCG were isolated
and characterized as having a mutation in dprE1, in which
Cysteine 387 had been replaced by a Glycine residue. This led us
to test these dprE1 mutants for their sensitivity to DNB1 and
DNB2 (Tables S4, S5). They all displayed resistance to the DNB
compounds corroborating our biochemical data (Figure 3F).
These findings demonstrate the remarkable intracellular vulner-
ability of DprE1 and highlight the importance of pursuing the
route of DPA production as a drug target.
Discussion
Although the location and state of latent bacteria remains a
matter of debate [22], one commonly shared hypothesis for
mycobacterial persistence is that M. tuberculosis bacilli are able to
survive in macrophages for prolonged periods of time and, unlike
other bacteria, are able to actively replicate. It has clearly been
established that the tubercle bacillus adopts a different phenotype
in the host macrophage’s phagosome compared to growth in
extracellular conditions [7,8]. The intraphagosomal transcription
profile of M. tuberculosis is complex; a large variety of genes are
over-expressed and temporally regulated in response to environ-
mental cues. Altogether, this makes the identification of one
specific factor in the tubercle bacillus that could be selected as the
ideal drug target difficult. Consequently, non-target cell-based
assays have emerged as a critical tool in the search for intracellular
M. tuberculosis inhibitors.
Identification of antimycobacterial inhibitors active within host
cells has long been limited due to cumbersome CFU plating, slow
bacillary growth, safety requirements and difficulties in setting-up
appropriate infection conditions. As a consequence, this approach
was always used as a secondary assay after the initial selection of
High Content Screening on TB Infected Macrophages
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advent of automated confocal microscopy, the above-mentioned
limitations could be circumvented and here we demonstrate the
feasibility of large scale compound screening. To minimize the
steps and to cope with HTS requirements, we performed
suspension macrophage batch infection. To this end, careful
attention was paid to remove the extracellular non-phagocytosed
mycobacteria through the use of judicious centrifugation condi-
tions and amikacin. Mycobacteria are able to grow independently
of host cells and consequently any remaining extracellular bacilli
would greatly compromise the validity of our model. Consequent-
ly, an extra amikacin treatment step was added to the protocol to
Figure 2. MIC (mM) for different nitrobenzamides against M. tuberculosis H37Rv growth. Extracellular and Intracellular correspond to
growth in broth and in macrophages. DNB1 and DNB2 are compound 8 and 7 respectively.
doi:10.1371/journal.ppat.1000645.g002
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steps after amikacin treatment removed the antibiotic thereby
minimizing the introduction of any bias towards compounds that
could act synergistically with amikacin during screening. Thus
with the optimized protocol, there are almost no non-phagocy-
tosed mycobacteria left by the time compounds are added. Our
results demonstrate that our assay specifically measured the effect
of compounds on intracellular mycobacteria. Indeed, we observed
weak inhibition with rifampin, an antibiotic that is known to be
poorly active on intracellular mycobacteria. The reproducible
100-fold decrease in MIC for rifampin in the intracellular assay
compared to the in vitro growth assay proved that the targeted
bacteria are not extracellular. Otherwise no difference would have
been seen in MIC between the two assays. As is well established
and as we confirmed, macrophages are able to support high
bacterial loads, which occupy a large part of the cell cytoplasm,
eventually leading to macrophage cell death. Taking this into
account, it was decided to set the data acquisition at day 5 post-
infection when the cell number in the DMSO-control samples had
significantly decreased relative to the antibiotic protected controls.
Thus, monitoring cell number was an additional parameter
enabling us to confirm the compound’s antibacterial activity.
This confocal imaging-based assay could likely be adapted to other
t y p eo fc e l l ss u c ha sn o n - p h a g o c y t e si nw h i c hM. tuberculosis is known
to reside [3,6]. Firstly, one couldenvision searching for drugs that will
be active in different host settings. Secondly, our system could be
adapted to the screening of compounds that target mycobacterial
granulomas as these multi-cellular structures can be generated in vitro
[23] and have been shown to promote infection [24].
One of the current challenges for TB drug discovery is the
identification of compounds that are active against MDR and
XDR bacteria. Compound-based approaches have lately proven
Figure 3. DNB1 activity confirmation and target identification. (A) Structure of DNB1 (B) Profile in intracellular assay from DNB1 of the
benzamide scaffold; black squares and gray circles correspond to percentage of infected cells and host cell number (C) inhibition of the in vitro
growth fluorescence assays by DNB1; black triangles correspond to relative fluorescent units. Results (mean+/2SD from 5 independent experiments)
were normalized according to DMSO and INH control values. (D) Representative pictures of human primary macrophages infected with M.
tuberculosis H37Rv-GFP (MOI 2.5:1) at day 7 for DNB1 and INH (5 mM) and DMSO. NI: non infected. Scale bar corresponds to 50 mm. (E) Dose-response
curve for DNB1 on M tuberculosis H37Rv-GFP infected mouse bone marrow-derived macrophages and human primary macrophages after 5 days of
infection. Results are representative of 2 independent experiments. (F) Effect of DNB1 on the synthesis of decaprenyl-phospho-arabinose (DPA) by
cell-free extracts of M. smegmatis. Bacterial extracts were treated with 4 mM (1.4 mg/mL) of DNB1 for 30 min at 37uC prior to the addition of p(
14C)Rpp
and ATP and further incubation for 90 min at 37uC. The same amount of reaction material was loaded as for the control (CTL). PRPP, 5-phosphoribosyl
1-pyrophosphate; DPPR, decaprenylphosphoryl 5-phosphoribose; DPR, decaprenyl-phospho-ribose.
doi:10.1371/journal.ppat.1000645.g003
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and have identified compounds with new mechanisms of actions
such as TMC207 [25,26]. The library of compounds that we
screened contained more than 1,500 different heterocycles and
was initially designed to be unbiased. This led to the identification
of 23 clusters of molecules, among which the only known anti-
tubercular compounds were INH derivatives. However, screening
of another library led to a list of another set of hits including
analogs of the nitroimidazopyran PA-824 [15] (data not shown).
Also, our set of compounds does not include the typical chemical
structures of some common antibacterials such as rifampin and
streptomycin, which do not meet the Lipinski criteria on size and
lipophilicity used for our library selection [27]. Taken together,
this showed that the 57,000 member library does not contain the
full repertoire of active small molecules.
The step-like shape of the dose-response curves (DRC) resulting
from this cell-based phenotypic assay is unusual compared to the
classical sigmoid profile of DRC for in vitro enzymatic or ligand-
receptor type based assays. However, we can clearly rule out
possible artifacts such as precipitation for several reasons. Firstly,
our assay was calibrated with known TB inhibitors such as INH
and ethambutol, which are water soluble and the curves obtained
with these compounds displayed step-like shape. Secondly, the
classical sigmoid with Hill coefficient value around 1 correspond to
a fitting equation whose parameters are based on a model relying
on the interaction of one unique substrate/ligand with one
enzyme/receptor. In contrast, in our phenotypic assay, a large
number of proteins are likely to be involved in the inhibition
process, which may require compound intracellular uptake, pro-
drug activation and target inhibition. In this system, the classical
sigmoid model may not be the best fitting model. Thirdly, a similar
step-like shape is observed for classical microbiological assays on
whole mycobacterium such as for the rezasurin reduction assay.
Thus, determination of MIC values as used for conventional TB
drug susceptibility testing turned out to be more appropriate than
half maximal inhibitory concentration IC50 measurement.
Structure-activity relationship studies were thus undertaken on
the benzamide scaffold, which initially contained the largest
number of molecules identified from the screen after the INH-like
molecules. Cyclic-benzamides showed a 200-fold diminished
intracellular growth inhibitory effect relative to its in vitro
antibacterial effect, thereby demonstrating that compounds have
to be efficiently taken up by cells to be effective against the
intracellular bacillus. This intracellular assay may thus prove to be
suitable for counter selection of compounds that have impaired
membrane uptake.
Further development of the DNB series into lead compounds
active in vivo requires improvement of their pharmacokinetics
properties. Indeed, we observed that the nitro groups that are
necessary for DNB antimycobacterial activity were very rapidly
reduced into an amino group by mammalian liver enzymes. The
mean half-life of the most active DNB compounds was about
8 minutes in a mouse microsomes assay and could already be
significantly increased using encapsulation within nanoparticles. In
a preliminary experiment using the acute mouse model of
M. tuberculosis, a one log reduction of the CFU in the lungs of
DNB treated animals compared to non-treated controls was
observed after a three week daily treatment with 30 mg/kg/day
following an intranasal infection (data not shown). Additional
optimization of ADME properties and in vivo delivery of the DNB
compounds is currently in progress.
Strikingly, chemical genomics identified decaprenyl phospho-
ribose 29-epimerase as the main target of dinitrobenzamides. This
epimerase is encoded by dprE1 and dprE2 genes that are adjacent to
the embA-C gene cluster whose products are also involved in the
biosynthesis of LAM and AG and are targets of the first-line drug,
ethambutol [28]. Consistent with their involvement in the synthesis
of DPA, Rv3790c (DprE1) and Rv3791c (DprE2) have been
suggested to be essential for the in vitro growth of M. tuberculosis as
determined by transposon site hybridisation (TraSH) [29]. Inter-
estingly, the fact that potent inhibitors of DprE1 could directly be
isolated from the primary screening may indicate that this target is
not only essential for bacterial growth inside the macrophages but
also is easily accessible to small molecules. Though it is evident that
the presence of the DNB scaffold in our library largely contributed
to the identification of DrpE1 as a very druggable target, screening
ofanothernon-biased library couldhaveresultedinsimilarfindings.
This is supported by the fact that as part of an independent study,
DprE1 was recently identified as the target of benzothiazinones
(BTZ), a different class of compounds that show potent antimyco-
bacterial activity [21]. Moreover, BTZ-resistant mutants all
displayed cross-resistance indicating that two chemically un-related
nitro-compounds probably inhibit DPA production by the same
mechanism. Further biochemical analyses will definitely contribute
to a better understanding of the pharmacology of this new
druggable mycobacterial target.
The mechanisms of action of the other scaffolds found in this
study remains to be characterized and will likely contribute to the
discovery of new bacterial as well as cellular targets. For example,
derivatives from Scaffold IX (Table S1) are effective against XDR
isolates and have no effect against DprE1 activity and ATP
synthesis, which suggests that they may act on an unknown target.
In addition, molecules sharing Scaffold III displayed selective
inhibition of intracellular growth within macrophages, raising the
possibility that a host cellular target could be involved in the
antibacterial effect. Alternatively, using other libraries could lead
to the identification of scaffolds with different chemical structures.
For instance, screening another set of 120,000 molecules in our
cell-based assay revealed analogs of the nitroimidazopyran PA-824
[15], which was shown to induce bacterial killing by nitric oxide
release [30]. Taken together this clearly shows that both the
repertoire of druggable targets and potential antitubercular
compounds has not yet been fully uncovered. Finally, we would
like to point out that high throughput/content screening is a
powerful generic approach that can be used to discover inhibitors
for other intracellular pathogens that are genetically tractable.
Methods
Chemical Compounds
The 56,984-compound library was purchased from Timtec
(26,500 molecules), Cerep (10,484) and ChemBridge
TM (20,000)
and each sub-library consisted of a selection of molecules based on
their chemical diversity and drug-like properties. An in-house
evaluation showed that $80% of the compounds met the criteria
of the ‘rule of 5’ of Lipinski [31]. Small molecules from the
screening libraries, CPD1, N-(2-(4-methoxyphenoxy) ethyl)-3,5-
dinitrobenzamide (DNB1) and N-(2-(benzyloxy) ethyl)-3,5-dinitro-
benzamide (DNB2) were dissolved in pure DMSO (Sigma, D5879)
and added to the assay plates using an EVObird liquid handler
(PerkinElmer) to reach a final concentration of 20 mM.
Mycobacterial Strains and In Vitro Bacterial Growth Assay
The description of all the mycobacterial strains used in this study is
giveninTableS6.MycobacteriumtuberculosisH37Rv,H37Ra and BCG
Pasteur were used as reference strains. The recombinant strain of M.
tuberculosis H37Rv expressing the green fluorescent protein (H37Rv-
GFP) bears an integrative plasmid (based on Ms6) carrying a gfp gene
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precultured at 37uC in Middlebrook 7H9 broth (Difco) supplemented
with 0.05% Tween 80 (Sigma, P8074) and oleic acid-albumin-
dextrose-catalase (OADC) for 14 days. 384-well plates (Greiner,
#781091) were first preplated with 0.5 ml of compound dispensed by
EVOBird (Evotec) in 10 ml of Middlebrook 7H9-OADC medium
supplemented with 0.05% Tween 80. Forty microliters of H37Rv-
GFP bacterial suspension diluted to 2610
6 CFU/mL (based on GFP
fluorescence assessment and a reference curve) was then added to the
diluted compound resulting in a final volume of 50 ml containing 1%
DMSO. Plates were incubated at 37uC, 5% CO2 for 7 days.
Mycobacterial growth was determined by measuring GFP-fluores-
cence using a Victor 3 reader (Perkin-Elmer Life Sciences). The
resazurin reduction method was used for reference strains, MDR,
XDR and clinical isolates [33]. Isoniazid at 0.05 mg/mL and
1 mg/mL (Sigma, I3377), Rifampin at 1 mg/mL (Euromedex) and
DMSO were used as controls. Drug susceptibility testing on
benzothiazinone-resistant mycobacteria with various mutations in
the rv3790 gene was performed as recently reported [21].
Macrophage Infection Assay in 384-Well Plates, Image
Acquisition and Analysis
384-well Evotec plates (#781058) were first preplated with
0.5 ml of compound dispensed by EVOBird (Evotec) in 10 mlo f
RPMI 1640 (Gibco) supplemented with 10% heat-inactivated fetal
calf serum (FCS, Gibco). Raw 264.7 (ATCC # TIB-71) (1.5610
8
cells) were infected with H37Rv-GFP [32] in suspension at a MOI
of 1:1 in RPMI 1640 supplemented with 10% heat-inactivated
FCS for 2 hours at 37uC with shaking. After two washes by
centrifugation, the remaining extracellular bacilli in the infected
cell suspension were killed by a 1 hour Amikacin (20 mM, Sigma,
A2324) treatment. After a final two-wash centrifugation, 10 000
infected cells were dispensed into each plate well pre-plated with
compounds and controls. Infected cells were then incubated for 5
days at 37uC, 5% CO2. After five days, macrophages were stained
with SYTO 60, 5 mM (Invitrogen, S11342) for 1 hour at 37uC and
image acquisition was performed on an EVOscreen-MarkIII fully
automated platform (PerkinElmer) integrated with an Opera
TM
(20X-water objective, NA 0.70) and located in a BSL-3 safety
laboratory. Mycobacteria-GFP were detected using a 488-nm laser
coupled with a 535/50 nm detection filter and SYTO 60 labelled
cells with a 635-nm laser coupled with a 690/40 nm detection
filter. Four fields were recorded for each plate well and each image
was then processed using dedicated in-house image analysis
software (IM) described elsewhere [14]. Briefly, the algorithm first
segments the cells on the red channel using a sequence of
processing steps [13]. Firstly the contour of each macrophage is
delineated using an algorithm based on the intensity signal given
by the red channel (Figure 1B). The number of red delineated
surfaces corresponds to the number of macrophages. The host cell
is then considered to be infected by M. tuberculosis if there is an
overlap of at least 3 pixels in the green channel above a given
intensity threshold within the cell surface. The ratio of infected
cells to the total number of cells determines the percentage of
infected cells. Another parameter deduced from the images is the
bacterial load that refers to the total surface area of all the green
objects that partly cover the delineated macrophages.
Primary Component Analysis (PCA) for High Content
Analysis
Eight parameters that include cell number, cell surface, infected
cell number, number of green objects, green object intensity, green
object surface, green surface in infected cells and infection ratio
were then processed plate by plate in a PCA protocol developed
using PipelinePilot
TM (Accelrys). Briefly, the values from both
positive and negative controls of each plate were first used to
create a PCA model in 1 dimension for the plate (Minimum
Variance explained=0.75, Center-and-Scale data pre-transfor-
mation). The model was then applied to calculate the new
coordinates of compounds and controls for that plate. Similar
analysis was then repeated for each new screened plate. A Z9 score
was then calculated, and controls and plates were accepted with a
Z9 score above 0. For each plate, the model described more than
99% of the variance. PCA-1x analysis improved active compound
separation compared to the analysis based on the infected cell
percentage parameter as demonstrated by achievement of better
Z9 values (Figure S2B). Hits were selected with a PCA-1x value
below 0.5, corresponding to the separation value between the
DMSO and the INH 1 mg/mL populations.
Primary Screen and Hit Confirmation
The compound library was screened at a single concentration of
20 mM. Hits were then cherry-picked and tested in ten- 2-fold
serial dilutions (from 20 mM to 0.5 nM) in duplicate. 486 hits
(0.85%) were then confirmed.
Statistics
Data obtained from either the intracellular assay image analysis
or from the conventional antibacterial assay were then processed
using ActivityBase (IDBS) to calculate statistical data (% of
inhibition, Z score for each compound, Z9, coefficient of variation
(CV) etc. for the control plates). Results visualization was
performed with Spotfire (Tibco). If not specified in the figure
legend, data are expressed as mean+/2SD from 2 independent
experiments.
Infection of Primary Macrophages and CFU
Determination
Mouse bone-marrow-derived macrophages were obtained by
seeding 10
7 bone marrow cells from C57BL/6 mice in 75 cm
2
dishes in RPMI 1640 (Gibco
TM) supplemented with 10% heat-
inactivated FCS and 10% L-cell conditioned medium (L-929).
Peripheral Blood Mononuclear Cells (PBMC) were isolated from
buffy coat from healthy volunteers. 15 ml of Ficoll-Paque Plus
(Amersham Biosciences, Sweden) were added to PBS diluted buffy
coat diluted and centrifuged at 25006g for 20 min. PBMC were
obtained by CD14
+ beads separation (Miltenyi Biotec, Germany),
washed 3-times with PBS containing 1% FCS and transferred to
75 cm
2 culture flask containing RPMI 1640 media, 10% FCS and
50 ng/ml of recombinant-human macrophage colony stimulating
factor (rh-MCSF, R & D systems, Minneapolis). After 6 days,
murine or human macrophages were harvested with Versene
(Gibco
TM) and seeded at a density of 1.5610
4 cells per well in 384-
well Evotec plates in 50 ml RPMI 1640 supplemented with 10%
heat-inactivated FCS and 10% L-929 or 50 ng/ml of rh-MCSF
respectively. Adherent cells were then infected with bacterial
suspensions at a MOI of 2.5 to 1 bacteria per cell and incubated
for 2 h. Cells were then washed three times with PBS
supplemented with 1% FCS and further incubated with different
concentration of DNB compounds for 7 days. Cells were then
lysed with 0.1% Triton X-100 (Sigma) in H2O and serial dilutions
were performed to quantify CFUs as previously reported [34].
Frequency of Spontaneous Resistance
The frequency of spontaneous mutation was determined on
7H10-OADC plates containing increasing concentrations of
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5,1 0
6,1 0
7 and
10
8 CFU containing bacterial suspensions were spread on
dinitrobenzamides containing agar plates. After 5–6 weeks at
37uC, colonies were counted and frequency of mutation was
evaluated as the ratio of colonies grown relative to the original
inoculum. DMSO and INH were used as negative and positive
controls respectively.
Effects of Inhibitors on the Formation of DPA In Vitro
Reaction mixtures contained 1 mg of M. smegmatis membrane
and cell wall (P60) proteins [20], 80 mM ATP, 120,000 dpm
p(
14C)Rpp [35], 50 mM MOPS pH 7.9, 5 mM 2-mercaptoetha-
nol and 10 mM MgCl2. Reactions were stopped by the addition of
CHCl3:CH3OH (2:1) and the organic phase backwashed with
CHCl3:CH3OH:H2O (3:47:48). After drying under N2, the
radiolabeled material was dissolved in CHCl3:CH3OH:H2O:
NH4OH (65:25:3.6:0.5) for TLC analysis.
Effects of Inhibitors on Mycobacterial Cell Wall Synthesis
For assessing the effects of DNB1 and DNB2 on whole M.
tuberculosis H 3 7 R a ,0 . 6t o8 0mM( 0 . 2t o2 8mg/mL respectively)
of the compounds were added to bacterial cultures grown to
mid-log phase in glycerol-alanine-salts medium and incubated
for 16 hrs at 37uC with shaking, after which 1 mCi/mL
[U-
14C]glucose (specific activity, 317 Ci mol
21,M PB i o m e d i -
cals Inc.) or 0.5 mCi/mL [1,2-
14C]acetic acid (specific activity,
60 Ci mol
21, NEN Radiochemicals) were added and the
cultures were incubated for another 24 hrs at 37uC. Untreated
and inhibitor-treated bacteria were collected by centrifugation,
washed and their lipids, lipoglycans (LM and LAM) and
mycolyl-arabinogalactan-peptidoglycan (mAGP) complex, were
extracted essentially as described [36].
14C-glucose- and
14C-
acetate-derived lipids and fatty acids (including mycolates) were
analyzed by TLC on silica gel 60 aluminum-backed plates
(Merck, Darmstadt, Germany) in a variety of solvent systems
[37].
14C-glucose-derived lipoglycans were separated on Tricine
gels, transferred to nitrocellulose membranes and revealed by
autoradiography. The amount of radioactivity incorporated into
the individual sugars of the mAGP complex was determined by
hydrolysis of the
14C-glucose-derived material with 2M
CF3COOH for 3 hrs at 120uC and separation of the individual
monosaccharides (upon removal of fatty acids) on aluminum-
backed TLC plates developed twice in pyridine:ethyl acetate:
acetic acid:water (5:5:1:3). Autoradiograms were produced by
exposure of the TLCs and nitrocellulose membranes to
KODAK-Biomax MR films at 270uC.
Supporting Information
Figure S1 Quantification of M. tuberculosis growth into macro-
phages by automated confocal imaging. Image-based quantifica-
tion of (A) percentage of infected cells and (B) the total number of
cells from 2 hours to day 7 after infection with H37Rv-GFP at a
multiplicity of infection of 0.5 (gray squares), 1 (black circles) and 2
(dark gray triangles). Non-infected cells (black diamonds) were
used as the negative control. Results are representative of 2
independent experiments.
Found at: doi:10.1371/journal.ppat.1000645.s001 (0.04 MB PDF)
Figure S2 Overview of large scale screening on the M. tuberculosis
infected macrophages. (A) Large-scale batch-based macrophage
infection assay sequence. (B) Comparison of Z9 score (DMSO vs
INH 7 mM( 1 mg/mL)) calculated with percentage of Infected
Cells (x-axis, classical method) or after PCA-1x analysis (y-axis).
The line represents the y=x equation. Most of the Z9 scores
calculated after PCA-1x analysis are higher demonstrating a better
separation between active and non-actives compounds. (C) Hit
CPD1 profile in the intracellular assay showing major cytotoxicity
above 5 mM. Results (mean+/2SD from 2 independent experi-
ments) were normalized according to DMSO and INH control
values. Black squares and gray circles correspond to the
percentage of infected cells and the host cell number respectively
as determined by our customized image analysis for the
intracellular assay.
Found at: doi:10.1371/journal.ppat.1000645.s002 (0.16 MB TIF)
Figure S3 Dose-response analysis of Compounds 1 to 12-(S)
listed in Table 2 in in vitro intracellular and in broth grown
bacterial assays. Percentage of inhibition of intracellular growth
from infected cells parameter (black squares) and extracellular
growth (gray triangles) Results are shown as the mean of 2
independent experiments with standard deviation (SD).
Found at: doi:10.1371/journal.ppat.1000645.s003 (0.09 MB TIF)
Figure S4 DNB1 and DNB2 exhibited a time dependent
inhibitory effect and inhibited M. tuberculosis arabinans biosyn-
thesis. (A) Kinetics of DNB1 (3 mM, black triangles and DNB2 at
(3 mM, black circles) bactericidal activity on M. tuberculosis H37Rv
growth in vitro. DMSO-treatment was used a control (gray
squares). Effect of DNB1 and DNB2 on the synthesis of the
arabinan domains of arabinogalactan (B) and LAM (C) in M.
tuberculosis. After incubation of bacterial cultures with 40 and
80 mM (14 mg/mL and 28 mg/mL) of compounds as described in
Materials and Methods, lipoglycans and cell wall monosaccharides
were purified before being loaded onto TLC. Equal volumes and
cpm counts were loaded for lipoglycans and cell wall monosac-
charides respectively, for control (CTL) and samples. Monosac-
charides were identified by co-migration with commercial
standards (Ara, arabinose; Gal, galactose; Glc, glucose). Results
are representative of 2 independent experiments.
Found at: doi:10.1371/journal.ppat.1000645.s004 (0.15 MB TIF)
Table S1 Chemo-informatic cluster analysis of the 135 con-
firmed hits
Found at: doi:10.1371/journal.ppat.1000645.s005 (0.04 MB PDF)
Table S2 Cytotoxicity and antibacterial spectrum of DNB1 and
DNB2
Found at: doi:10.1371/journal.ppat.1000645.s006 (0.02 MB PDF)
Table S3 Proportion of spontaneous resistant mutants for DNB1
and DNB2
Found at: doi:10.1371/journal.ppat.1000645.s007 (0.02 MB PDF)
Table S4 DNB effect on M. smegmatis mc
2 155 mutants in DprE1
Found at: doi:10.1371/journal.ppat.1000645.s008 (0.01 MB
DOC)
Table S5 DNB effect on M. bovis BCG mutants in DprE1
Found at: doi:10.1371/journal.ppat.1000645.s009 (0.01 MB PDF)
Table S6 List of mycobacterial strains used in this study
Found at: doi:10.1371/journal.ppat.1000645.s010 (0.01 MB PDF)
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